



Press release |

IBA'S FAMILY OF PROTON BEAM SOLUTIONS SUITS DIVERSE BUDGETS, SITES AND CLINICAL NEEDS

MIAMI BEACH, Oct. 1, 2011 — IBA Particle Therapy now offers a range of Proton Therapy solutions for cancer specialty centers planning to treat from 250 to 2,000 patients annually with protons.

The Proteus® series of Proton Therapy solutions can accommodate disparate budgets, building sites, and clinical needs for cancer centers eager to offer advanced radiotherapy with fewer clinical consequences. Each solution combines the latest imaging and therapeutic innovations with more than 20 years of proton experience that IBA has gained from its radiation oncology partnerships worldwide.

“IBA’s full line of Proton Therapy solutions can fulfill the unique requirements of most any academic health center, community hospital or physician’s group looking to add proton treatments to its cancer-fighting armamentarium,” said Pierre Mottet, Chief Executive Officer of IBA.

IBA will feature the flexible Proteus proton alternatives in booth #1813 at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held Oct. 2 – 6 in Miami Beach, Florida.

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, and sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

The largest and most versatile Proton Therapy solution, Proteus PLUS™, can serve up to four treatment rooms and as many as 2,000 patients a year. Cancer centers may choose from four different proton beam delivery modes (Single Scattering, Double Scattering, Uniform Scanning and Pencil Beam Scanning) using IBA’s treatment-optimized Universal Nozzle. Or they may deploy a dedicated Pencil Beam Scanning Nozzle.

With Proteus PLUS, cancer centers may equip each patient treatment room with their choice of a G360 iso-centric gantry, a fixed-beam or IBA’s new G220 compact gantry. For cramped building sites common to urban centers, IBA’s unique Vbeam® technology can deliver protons vertically to the treatment level and then horizontally to patient treatment rooms located on the floor above the proton-generating cyclotron.

Proteus TK2™, a collaboration of three powerhouses in advanced cancer care technologies, is a turnkey proton therapy facility suited for cancer centers that intend to treat 500 to 1,000 patients a year with protons. It incorporates the major elements of a two-room proton beam facility, from building design and construction to technology integration, for optimal patient care.



Press release |

The cyclotron, beam line, G360 iso-centric gantry and a fixed-beam are provided by IBA. Royal Philips Electronics provides advanced imaging technologies, including a CT, with optional CT SIM and MRI. Philips Ambient Experience Design solutions provide patient-comforting interior spaces. Elekta provides all cancer workflow and patient management tools.

The single-room solution, Proteus ONE™*, was conceived by IBA engineers to provide a smaller, less costly option for cancer centers that may not have the budget or real estate to develop a comprehensive, multiroom Proton Therapy facility. It can treat 250 to 500 patients a year. More Proteus ONE systems may be added to meet increased patient demand.

Proteus ONE is about the size of two typical linac vaults. Unlike previous systems, this single-treatment-room solution may be housed in a small building addition to an existing facility. Proteus ONE is composed of an advanced non-superconductive cyclotron; an integrated Cone Beam CT; a newly designed, compact gantry and patient-friendly treatment room.

**Proteus ONE™ is the brand name of a new configuration of the Proteus® 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

ABOUT IBA

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: www.iba-worldwide.com

Contact

Media Contact:

Bill Brozak

612-305-6221

bill.brozak@collemcvoy.com

IBA

Bill Hansen

Director of Global Marketing

Phone: 612-804-5559

Email: william.hansen@iba-group.com